Background-Although a heritable basis for sudden cardiac death (SCD) is suggested by the impact of family history on SCD risk, common genetic determinants have been difficult to identify. We hypothesized that a common variant at chromosome 9p21 related to myocardial infarction would influence SCD risk. Methods and Results-This was a prospective, nested, case-control analysis among individuals of European ancestry enrolled in 6 prospective cohort studies. Study subjects were followed up for development of SCD, and genotypes for rs10757274 were determined for 492 sudden and/or arrhythmic deaths and 1460 controls matched for age, sex, cohort, history of cardiovascular disease, and follow-up time. Conditional logistic regression with fixed-effects meta-analysis assuming an additive model was used to test for associations. When individual study results were combined in the meta-analysis, each increasing copy of the G allele at rs10757274 conferred a significantly elevated age-adjusted odds ratio for SCD of 1.21 (95% confidence interval, 1.04 to 1.40; Pϭ0.01). Controlling for cardiovascular and lifestyle risk factors strengthened these relationships (odds ratio, 1.29 per G-allele copy; 95% confidence interval, 1.09 to 1.53; Pϭ0.003). These results were not materially altered in sensitivity analyses limited to definite SCD, in models that further controlled for the development of interim cardiovascular disease, or when the highly correlated variant rs2383207 was tested. Conclusions-The major allele of a single-nucleotide polymorphism previously associated with increased risk of coronary artery disease events is associated with increased risk of SCD in individuals of European ancestry. Study of the mechanism underlying this association may improve our understanding of lethal cardiovascular disease. (Circulation.
S
udden cardiac death (SCD) results in 250 000 to 400 000 deaths in the United States annually. [1] [2] [3] Coronary heart disease (CHD), with or without myocardial infarction (MI), is the most common substrate underlying SCD in the Western world, being responsible for Ϸ75% of SCDs. 4 -7 However, the majority of individuals who die suddenly are not in recognized high-risk subsets, 8 and more than half have no clinically recognized heart disease before death. 9 Therefore, improved methods that more accurately identify individuals at risk for SCD within the general population are needed to significantly reduce the overall incidence of SCD. Because there is a heritable component to SCD risk, 10 -14 genetic factors may help us better identify those at risk.
Clinical Perspective on p 2068
To date, rare mendelian syndromes such as congenital long-QT syndrome or hypertrophic cardiomyopathy have been found to contribute to a minority of SCD cases in adults 15 but are typically the result of rare variants, private to individual families. 16 Although the majority of SCD cases occur in the general population rather than among high-risk subsets, 8 the overall annual incidence in middle-aged to older adults is low (0.1% to 0.4%). [17] [18] [19] Thus, few prospective studies have adequate power to examine the role of genetic variants in the primary prediction of SCD, and at present, the search for common variants relevant at the population level has met limited success. 20, 21 Common variants at a locus on chromosome 9p21 near the CDKN2A and CDKN2B genes have recently been associated with CHD and MI, [22] [23] [24] [25] [26] as well as abdominal aortic and intracranial aneurysms. 27, 28 We hypothesized that alleles of these common variants, which have been associated with multiple manifestations of vascular disease, might also be associated with SCD within the general population. To increase the number of SCD cases without decreasing our specificity for arrhythmic death, we chose to pool cases from 6 National Institutes of Health-funded prospective cohorts within the Brigham and Women's Hospital and the Harvard School of Public Health to test for an association between a common polymorphism at the 9p21 locus and SCD among individuals of European ancestry.
Methods

Study Populations
The study design is a case-control investigation sampled from prospective cohorts and clinical trials, taking advantage of the time-to-event data by matching cases and controls on follow-up time. The prospective cohorts included in the present investigation include the Physicians' Health Study (PHS I and II), the Nurses' Health Study (NHS), the Health Professionals Follow-Up Study (HPFS), the Women's Health Study (WHS), and the Women's Antioxidant Cardiovascular Study (WACS). Together, these cohorts include a total of 38 975 men and 67 093 women with stored blood samples. Details of the cohorts, along with the blood sample collection, are outlined in Table I of the online-only Data Supplement. In brief, the NHS and HPFS are prospective, observational cohort investigations; the PHS I, WHS, and WACS were initially randomized trials of aspirin and/or vitamin supplements in which treatment has ended. Prospective follow-up is ongoing in the PHS I and WHS. The PHS II is an ongoing randomized trial of vitamin supplementation. Information about medical history, lifestyle choices, and incident disease is assessed either annually or biennially by self-administered questionnaires.
End-Point Confirmation
The study end points included incident cases of sudden and/or arrhythmic cardiac death that occurred after return of the blood sample and before April 1, 2007. All cohorts used similar methods to document the timing and mechanism of cardiovascular deaths. 29 Next of kin or postal authorities reported most deaths, and at the completion of each mailing cycle, the National Death Index was searched for names of nonrespondents to the questionnaire. Death certificates were obtained from state vital statistics departments to confirm reported deaths; if death certificates indicated possible cardiovascular disease (CVD), permission to obtain further information from medical records was requested from family members. For deaths that occurred outside the hospital, descriptions of the circumstances surrounding these deaths were obtained from the next of kin. Medical records (hospital, emergency room, autopsy, and emergency medical services reports) and accounts of the death from next of kin for all possible cardiovascular deaths (excluding strokes) were then reviewed by 2 cardiologists, and deaths were classified according to timing (the length of symptoms preceding the terminal event) and mechanism (arrhythmic versus nonarrhythmic). Information from the death certificate was not used in the classification.
A cardiac death was considered a definite SCD if the death or cardiac arrest that precipitated death occurred within 1 hour of symptom onset as documented by medical records or next-of-kin reports (nϭ389, 72.6%) or had an autopsy consistent with SCD (ie, acute coronary thrombosis or severe coronary artery disease without myocardial necrosis or other pathological findings to explain death; nϭ23, 5.4%). Unwitnessed deaths or deaths that occurred during sleep in which the participant was documented to be symptom free when last observed within the preceding 24 hours and circumstances suggested that the death could have been sudden were considered probable SCDs (nϭ93, 17.4%). 4, 17, 30 Deaths were also classified as arrhythmic or nonarrhythmic on the basis of the definition of Hinkle and Thaler. 31 An arrhythmic death was defined as an abrupt spontaneous collapse of the circulation (pulse disappeared) without evidence of prior circulatory impairment (shock or congestive heart failure) or neurological dysfunction (change in mental status, loss of consciousness, or seizure). Deaths before which the pulse gradually disappeared and/or those preceded by circulatory or neurological impairment were considered nonarrhythmic deaths, and these deaths were excluded from the SCD end point even if the death occurred within 1 hour of symptom onset. Deaths that fulfilled the criteria for arrhythmic death but were preceded by Ͼ1 hour of symptoms (nϭ31, 5.8%) were also included in the combined end point of SCD and/or arrhythmic cardiac death.
A total of 540 sudden and/or arrhythmic deaths occurred among participants who donated blood samples at baseline ( Table 1 of the online-only Data Supplement), and 536 of these cases had DNA samples that passed our quality-control standards. Because very few SCD cases occurred among other ethnicities (nϭ20) in these predominantly white cohorts and to reduce the risk of population stratification, analyses were limited to SCDs among whites (nϭ516).
Selection of Controls
Using risk-set sampling, 32 we randomly selected up to 3 controls from the same cohort for each case. These controls were also matched on sex, age (Ϯ1 year), ethnicity, smoking status (current, never, past), time and date of blood sampling, fasting status, and presence or absence of CVD (MI, angina, coronary artery bypass graft surgery, or stroke) at the time of blood draw. For the 69 cases who developed CVD after the blood draw but before their SCD, we selected a second set of 3 controls who developed CVD after the blood draw to explore how much of the overall association with SCD might be explained by the development of nonfatal CVD before SCD.
Genotyping and Quality Control
Genomic DNA was extracted from the buffy coat fraction of centrifuged blood with Qiagen Autopure kits (Valencia, Calif) in the NHS, HPFS, and WACS and from whole blood in the PHS I. In the WHS and PHS I, DNA was extracted by use of the MagNA Pure LC instrument with the MagNA Pure LC DNA isolation kit (Roche Applied Science, Penzberg, Germany). All assays were conducted without knowledge of case status, and samples were labeled by study code only. Matched case-control pairs were handled identically, shipped in the same batch, and assayed in the same analytical run to avoid batch effects. A common variant at the chromosome 9p21 locus that has been associated with CVD (rs10757274) 23 was genotyped on the Sequenom platform (San Diego, Calif), which resolves allele-specific single-base extension products using mass spectrometry (MALDI-TOF) 33 As a backup, a second highly correlated variant (rs2383207) was also genotyped on the same platform. Samples with successful genotyping on Ͻ60% of quality-control single-nucleotide polymorphisms (SNPs) selected from HapMap (typically performing well on this platform) were excluded from analysis. Genotypes for both SNPs passed our quality-control thresholds (call rate Ն90%; Hardy-Weinberg equilibrium; PϾ0.01 in controls). Blinded replicate quality-control samples were included and genotyped with 100% concordance.
Statistical Analysis
Means or proportions for baseline cardiac risk factors were calculated for cases and controls. The significance of risk factor associations was tested with the 2 statistic for categorical variables and the Student t test for continuous variables. For each cohort, we investigated deviation from Hardy-Weinberg equilibrium using a 2 goodness-of-fit test. We analyzed the association between the SNP and the risk of SCD and/or arrhythmic cardiac death using conditional logistic regression analysis. With risk-set analysis, the odds ratio (OR) derived from the logistic regression directly estimates the hazard ratio and thus the rate ratio or relative risk. 32 Based on the genetic model underlying associations with CHD in prior studies, 22, 23 ORs were estimated for each cohort separately under an additive model of inheritance. The primary test of association was a fixed-effect meta-analysis conducted on the basis of the summary conditional logistic regression results for each cohort 34 ; PROC MIXED of SAS (SAS Institute Inc, Cary, NC) was used to pool effect estimates over study cohorts using inverse variance weights.
Tests for heterogeneity of the genetic effect across sites were conducted with the Q statistic. 35 To allow secondary analyses, we examined pooled conditional logistic regression models that directly combined the individual cohort data. Results were similar, so secondary analyses combined the individual data for simplicity. In these pooled analyses, we examined as a secondary analysis a 2-df test of the 3 genotypes that did not assume an additive mode of inheritance. We tested for deviation from additivity by placing an additive term and a term for the heterozygotes in the pooled model. In secondary analyses, we explored the relation between genotype and SCD across categories of age, sex, smoking, or the prevalence of known CVD at the time of the blood draw both through pooled stratified models and by adding cross-product terms between genotype and the exposure of interest into the full pooled multivariable model. These secondary analyses were exploratory; therefore, they must be considered in light of multiple testing and should be considered hypothesis generating.
For all combined analyses (meta-analyses and pooled), conditional logistic regression models adjusting for increasing levels of CHD risk factors were performed. Of the matching variables, age and smoking were not perfectly matched, so these variables were also entered into the conditional logistic regression models to avoid any potential for residual confounding. The first primary model adjusted for age only. The second further adjusted for standard cardiac risk factors, including body mass index and history of diabetes, hypertension, hyperlipidemia, and smoking (current, past, never). The third additionally adjusted for alcohol intake (less than weekly, weekly, daily, Ն2 drinks per day), physical activity (at least once per week), and aspirin use (Ն15 d/mo). The fourth further controlled for a family history of MI. Statistical analysis was performed with SAS statistical software, version 9.1 (SAS Institute, Inc).
Results
Study Sample Characteristics
A total of 516 cases (188 women and 328 men) of SCD and/or arrhythmic cardiac death occurred among whites in the 6 cohorts over an average follow-up of 13.0 years. The clinical characteristics recorded at the time of the blood draw for the 516 cases and the 1540 age-, sex-, smoking-and CVD-matched controls are displayed by study cohort in Table 1 . The mean age of the cases was 64.2 years, and 132 (25.6%) reported a history of CVD at the time of the blood draw. In pooled analyses, cases were more likely to report a history of diabetes and hypertension, to have a higher body mass index (PϽ0.001 for all comparisons), and to report a family history of MI (Pϭ0.05). Cases did not differ significantly from controls with respect to a history of hypercholesterolemia and/or aspirin use. Among the controls, cardiac risk factors at baseline were not associated with genotypes of the rs10757274 variant at the chromosome 9p21 locus, with the exception of a weak association with lower rates of diabetes with increasing copy of the G allele (Pϭ0.02; Table  II of the online-only Data Supplement).
Genotyping
The genotyping call rates were 99.4% for rs10757274 and 99.7% for the backup SNP rs2383207. There was no difference in the call rate between cases (99.2%) and controls (99.4%). Of the total study group, 492 cases and 1460 matched controls were successfully genotyped for rs10757274. No deviation from Hardy-Weinberg equilibrium was detected in controls in any of the cohorts. As has been demonstrated in prior studies, rs10757274 and rs2383207 are in strong linkage disequilibrium (r 2 ϭ0.87). Table 2 displays the individual age-adjusted cohort-specific associations for rs10757274 and sudden/arrhythmic death from conditional logistic regression models under an additive mode of inheritance. Allele frequencies in the control groups were relatively homogeneous (Pϭ0.29), and the pooled frequency was similar to that previously reported in other population-based cohorts of European ancestry such as the Atherosclerosis Risk in Communities and the Copenhagen City Heart Study. 22 The association between rs10757274 and sudden/arrhythmic death was relatively consistent across the 6 studies, although within-study probability values for the most part did not reach significance, likely because of the smaller sample size. In all of the cohorts except PHS II, increasing copies of the G allele were associated with a higher OR for sudden/arrhythmic death, and the test for heterogeneity of the ORs was nonsignificant (Pϭ0.34). When these ORs were combined in the meta-analysis, rs10757274 was significantly (Table 3 ) resulted in consistent associations for rs10757274, with slightly higher point estimates but overlapping CIs. In the full multivariable model, the OR was 1.29 per G-allele copy (95% CI, 1.09 to 1.53; Pϭ0.003). Results were not materially altered in sensitivity analyses limited to definite SCDs (nϭ384). Results were also unchanged after further adjustment for the interim development of nonfatal CVD after the blood draw (which occurred in 69 cases) by repeating the primary analysis with all cases but substituting a second set of controls matched for the development of CVD for these 69 cases (Table 3) .
Primary Association Meta-Analyses
Pooled Analyses
When the individual data from the cohort studies were pooled and analyses were repeated, the results were similar to those from the primary meta-analysis. Each increasing copy of the G allele of rs10757274 was associated with a significantly elevated OR for sudden/arrhythmic death of 1.21 (95% CI, 1.05 to 1.41) in the age-adjusted analysis. Further controlling for other cardiovascular and lifestyle risk factors had a similar impact on the risk estimate for rs10757274 (OR, 1.27; 95% CI, 1.09 to 1.50; Pϭ0.003). When examined in a 2-df model, the results were consistent with an underlying additive model, and the test for deviation from additivity was nonsignificant (Pϭ0.38). Compared with minor allele homozygotes, the OR for the heterozygotes in the full multivariable model was 1.12 (95% CI, 0.85 to 1.50) for rs10757274, and the major allele homozygotes had the highest risk (OR, 1.60; 95% CI, 1.16 to 2.20), consistent with an additive genetic model.
Stratified Analyses
In exploratory secondary analyses, we repeated the full pooled multivariable analysis after individually stratifying on each of the matching variables of age, sex, smoking, and history of prior CVD individually ( Table 4 ). The ORs associated with the risk allele were somewhat higher among those above the mean age of 64.2 years and among those with a history of prior CVD at the time of the blood draw, but the CIs for the risk estimates overlapped widely, and the P values for interaction in the full multivariable model were not significant. However, our power to detect such interactions is limited. Secondary analyses of the correlated SNP rs2383207 were very similar (data not shown).
Discussion
In this combined nested case-control analysis from 6 prospective cohorts, a common variant at the chromosome 9p21 Shown are individual cohort-specific and combined meta-analysis ageadjusted ORs (95% CIs) for increasing copies of the G allele of rs10757274 from conditional logistic regression models under an additive model of inheritance. Shown are the meta-analysis ORs (95% CIs) with increasing levels of risk factor adjustment for increasing copies of the G allele of rs10757274. *Sensitivity analysis: using only cases of definite SCD defined as death within 1 hour of the onset of symptoms or autopsy consistent with SCD (ie, acute coronary thrombosis or severe coronary artery disease without myocardial necrosis or other pathological findings to explain death).
†Secondary analysis: analysis repeated for the 492 cases using an alternative set of controls who developed CVD after the blood draw for the 69 cases who developed CVD after the blood draw. ‡Multivariable model 1: controlled simultaneously for age, smoking status (current, past, never), body mass index (continuous), and history of diabetes, hypertension, and high cholesterol. §Multivariable model 2: controlled for the variables in model 1 plus alcohol intake (less than weekly, weekly, daily, Ն2 drinks a day), physical activity (at least once per week), and aspirin use (Ն15 d/mo).
ʈMultivariable model 3: controlled for the variables in model 2 plus family history of MI.
locus, previously associated with MI and CHD, was significantly associated with sudden and/or arrhythmic death in individuals of European ancestry even after matching for prior CVD and controlling for cardiovascular risk factors. The risk allele is common, with Ϸ50% of the population carrying 1 copy and having an estimated 29% increased risk of sudden/arrhythmic death after other CHD risk factors are controlled for compared with noncarriers. For the Ϸ25% of the population who are homozygous for the risk allele, the OR of sudden/arrhythmic death was elevated by an estimated 60% compared with those homozygous for the minor allele. These data have important pathophysiological implications. The risk estimate observed here for SCD is remarkably similar to those previously reported for MI and coronary artery disease 22, 23, 25 and likely represents an association between this variant and a common underlying pathology (coronary atherosclerosis). However, the variant was associated with SCD even after matching for and further controlling for prior CVD. Therefore, the observed association is probably not entirely explained by the detection of underlying atherosclerosis. The present data, along with prior associations documented between this chromosomal region and aneurysmal diseases (abdominal aortic and intracranial aneurysms) 27, 28 and the progression of atherosclerosis, 36 suggest that the genetic locus may be involved in abnormal vascular remodeling and/or repair, which could increase the propensity toward more aggressive atherosclerosis and more unstable, rupture-prone atherosclerotic plaques, which could result in SCD.
Currently, the casual variant and mechanism underlying the association with vascular disease are not known. The SNP is located in a region on chromosome 9p21 of high linkage disequilibrium, 24, 26 which is devoid of known genes. The region is adjacent (Ϸ115 kb) to the coding sequences of 2 cyclin-dependent kinase inhibitor genes, CDKN2A and CDKN2B, which are known to have critical roles in cell proliferation, aging, senescence, and apoptosis 37 and which could play a role in atherosclerosis through their role in transforming growth factor-␤-induced growth inhibition. 38, 39 However, it is also possible that a previously unrecognized gene or regulatory element within or near the region could be the causal variant. Deep resequencing of this region is required to obtain the full spectrum of variation and to identify the causal variant(s).
These data may eventually have clinical implications as well. The modest risk elevation conferred by this variant is unlikely to have immediate implications for risk stratification in isolation. 40 However, given the 2-fold elevations associated with a family history of SCD and/or ventricular fibrillation, the 9p21 variant likely explains only a small fraction of the familial clustering of SCD. Therefore, it is likely that other susceptibility variants for SCD will be found, which, combined with other established and novel risk factors, may eventually allow the identification of a population at higher risk. Further investigation into the underlying mechanism may also lead to important insights into the underlying biology and point to novel causal pathways that can be targeted for intervention.
The present study has several strengths and limitations that warrant consideration. Strengths include the nested prospective case-control design, the large well-characterized cohorts, and the combined large number of rigorously confirmed SCD and/or arrhythmic cardiac deaths, a difficult phenotype to classify in population studies. Ascertaining cases and controls prospectively from a defined cohort reduces selection bias, and the ability to match on time at risk reduces the risk of survival bias. Potential limitations of this population-based study include the possibility of some degree of misclassification, particularly among the probable SCDs. However, results were unchanged when these probable SCDs were excluded from analysis. In addition, not all participants provided a blood sample (Table I of the online-only Data Supplement); therefore, these cases and controls could have differed in some respects from their respective source populations. Given the low frequency at which SCD occurs in the general population, we needed to combine cases from independent cohorts to achieve adequate power without decreasing our specificity for arrhythmic death, and the small numbers within each cohort did not allow us to independently replicate the association. However, the association has previously been replicated repeatedly with respect to other CHD end points. Moreover, these cohorts were composed of health professionals and used similar methodology for end-point documentation and risk factor ascertainment.
Population stratification (differences in ancestry between cases and controls) is a concern in any genetic association study and, if present, can lead to false inference of association for variants that have differing frequencies in different Models controlled simultaneously for age; smoking status (current, past, never); body mass index (continuous); history of diabetes mellitus, hypertension, and high cholesterol; family history of MI; alcohol intake (less than weekly, weekly, daily, Ն2 drinks a day); physical activity (at least once per week); and aspirin use (Ն15 d/mo).
†The smoking-stratified analyses did not control for smoking status.
ancestral groups. However, the 2 variants tested, rs10757274 and rs2383207, are highly correlated only in European ancestry samples, and the concordance of the association results for the 2 SNPs in our samples of self-described white individuals provides strong evidence against the possibility of a falsepositive association resulting from population stratification. Finally, the results observed in these cohorts composed entirely of health professionals may not apply to individuals in other socioeconomic strata who may be at higher risk for CVD or nonwhite populations, particularly blacks in whom the association between these variants and CHD has not yet been replicated. 22 
Conclusions
In this combined population of white men and women, a common variant at the chromosome 9p21 locus was associated with significantly increased risks of SCD and/or arrhythmic cardiac death, and this relationship was independent of established risk factors for CHD and/or SCD. These findings emphasize the important role that atherosclerosis plays in SCD even among relatively healthy free-living populations and may carry implications for further efforts to screen and prevent SCD in the general population. Because the majority of SCDs do not occur in high-risk individuals, 8, 9, 29 improved identification of those at risk is crucial to reducing SCD mortality.
